MAPK14 and Alzheimer disease: As at least 1 brain-penetrant specific MAPK14 inhibitor is currently in imaging and cerebrospinal fluid amyloid biomarker-based phase 2a clinical trials in patients with AD (clinicaltrials.gov; NCT02423122 & NCT02423200), we may soon learn how these preclinical observations translate to human disease.